New combo therapy aims to extend life in elderly esophageal cancer patients
NCT ID NCT07196345
First seen Sep 30, 2025 · Last updated Apr 29, 2026 · Updated 22 times
Summary
This study tests a combination of the chemotherapy drug TAS-102 and radiation therapy in people aged 65-85 with advanced esophageal cancer that has not spread widely. The goal is to find the best dose and see if the treatment helps patients live longer and controls the cancer. About 45 participants will be enrolled across multiple hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.